Camallergy (Cambridge Allergy Ltd) a biopharmaceutical company dedicated to providing innovative, patient-centric treatments for life-threatening food allergies, has announced it’s been awarded £1.1M funding under the Innovate UK Biomedical Catalyst Award program administered by Innovate UK, the United Kingdom’s research and innovation agency.
It is hoped that the funding will accelerate the development of the peanut allergy immunotherapy for planned phase 3 trials.
For more information, visit the Camallergy website – www.camallergy.com/
Enter your details below and we’ll email you our printable guide featuring the symptoms to look out for and what to do in an emergency.
You’ll also receive our monthly Allergy Outlook email with our latest news, updates and resources straight to your inbox.